TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Wang, Ning ^a,b   Zhang, Hui ^a   Yao, Qin ^b   Wang, Yankui ^b   Dai, Shuzhen ^b   Yang, Xingsheng ^a  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

chemoresistance; methylation; Ovarian cancer; paclitaxel; transforming growth factor beta inducible gene h3

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; PACLITAXEL; PROTEIN; TRANSCRIPTION FACTOR RUNX3; TRANSFORMING GROWTH FACTOR BETA INDUCIBLE PROTEIN H3; UNCLASSIFIED DRUG; BETAIG H3 PROTEIN; BETAIG-H3 PROTEIN; DNA; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER CELL; CANCER RESISTANCE; CELL ASSAY; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; OVARY TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CANCER STAGING; CARCINOMA; DRUG RESISTANCE; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; CARCINOMA; CELL LINE, TUMOR; DNA METHYLATION; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROMOTER REGIONS, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84862808609     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-6     Document Type: Article

References (27)

1. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. Siegel R, Ward E, Brawley O, Jemal A, CA Cancer J Clin 2011 61 212 236 10.3322/caac.20121 21685461
2. Novel agents in ovarian cancer. Matei D, Expert Opin Investig Drugs 2007 16 1227 1239 10.1517/13543784.16.8.1227 17685871 (Pubitemid 47317013)
3. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. McGuire WP, Hoskins WJ, Brady MF, et al. N Engl J Med 1996 334 1 6 10.1056/NEJM199601043340101 7494563 (Pubitemid 26012496)
4. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Taniguchi T, Tischkowitz M, Ameziane N, et al. Nat Med 2003 9 568 574 10.1038/nm852 12692539 (Pubitemid 36597103)
5. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Ferrandina G, Zannoni GF, Martinelli E, et al. Clin Cancer Res 2006 12 2774 2779 10.1158/1078-0432.CCR-05- 2715 16675570
6. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Yoshikawa H, Matsubara K, Qian GS, et al. Nat Genet 2001 28 29 35 11326271 (Pubitemid 32405812)
7. Causal relationship between the loss of RUNX3 expression and gastric cancer. Li QL, Ito K, Sakakura C, et al. Cell 2002 109 113 124 10.1016/S0092-8674(02)00690-6 11955451 (Pubitemid 34327521)
8. Cancer epigenetics. Momparler RL, Oncogene 2003 22 6479 6483 10.1038/sj.onc.1206774 14528271 (Pubitemid 37372327)
9. The history of cancer epigenetics. Feinberg AP, Tycko B, Nat Rev Cancer 2004 4 143 153 10.1038/nrc1279 14732866 (Pubitemid 38198742)
10. Epigenetics in cancer. Esteller M, N Engl J Med 2008 358 1148 1159 10.1056/NEJMra072067 18337604 (Pubitemid 351398489)
11. High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array. Yoon MS, Suh DS, Choi KU, et al. Oncol Rep 2010 24 917 925 20811671
12. OPCML at 11q25 is epigenetically inactivated and has umor-suppressor function in epithelial ovarian cancer. Sellar GC, Watt KP, Rabiasz GJ, et al. Nat Genet 2003 34 337 343 10.1038/ng1183 12819783 (Pubitemid 36792869)
13. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Zhang H, Zhang S, Cui J, Zhang A, Shen L, Yu H, Aust N Z J Obstet Gynaecol 2008 48 505 509 10.1111/j.1479-828X.2008. 00892.x 19032668
14. The epigenetics of ovarian cancer drug resistance and resensitization. Balch C, Huang TH, Brown R, Nephew KP, Am J Obstet Gynecol 2004 191 1552 1572 10.1016/j.ajog.2004.05.025 15547525 (Pubitemid 39491180)
15. Hypermethylation of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Tamura G, World J Gastrointest Oncol 2009 1 41 46 10.4251/wjgo.v1.i1.41 21160773
16. cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD, Purchio AF, DNA Cell Biol 1992 11 511 522 10.1089/dna.1992.11.511 1388724
17. Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells. Zhao YL, Piao CQ, Hei TK, Oncogene 2002 21 7471 7477 10.1038/sj.onc.1205891 12386809 (Pubitemid 35305574)
18. Epigenetic inactivation of Betaig-h3 gene in human cancer cells. Shao G, Berenguer J, Borczuk AC, Powell CA, Hei TK, Zhao Y, Cancer Res 2006 66 4566 4573 10.1158/0008-5472.CAN-05-2130 16651406
19. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Ahmed AA, Mills AD, Ibrahim AE, et al. Cancer Cell 2007 12 514 527 10.1016/j.ccr.2007.11.014 18068629 (Pubitemid 350199074)
20. Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR. Shah JN, Shao G, Hei TK, Zhao Y, BMC Cancer 2008 8 284 10.1186/1471-2407-8-284 18834524
21. TGFBI expression is associated with a better response to chemotherapy in NSCLC. Irigoyen M, Pajares MJ, Agorreta J, et al. Mol Cancer 2010 9 130 10.1186/1476-4598-9-130 20509890
22. The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Ying J, Srivastava G, Hsieh WS, et al. Clin Cancer Res 2005 11 6442 6449 10.1158/1078-0432.CCR-05-0267 16166418 (Pubitemid 41338980)
23. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer. Kang S, Dong SM, Park NH, Gynecologic oncology 2010 118 58 63 10.1016/j.ygyno.2010.03.025 20421128
24. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Staub J, Chien J, Pan Y, et al. Oncogene 2007 26 4969 4978 10.1038/sj.onc.1210300 17310998 (Pubitemid 47172647)
25. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Zhang X, Yashiro M, Ren J, Hirakawa K, Oncol Rep 2006 16 563 568 16865256
26. FANCF methylation contributes to chemoselectivity in ovarian cancer. Olopade OI, Wei M, Cancer Cell 2003 3 417 420 10.1016/S1535-6108(03)00111-9 12781358 (Pubitemid 38340287)
27. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. Li M, Balch C, Montgomery JS, et al. BMC Med Genomics 2009 2 34 10.1186/1755-8794-2-34 19505326